Technical Momentum: Nutriband Inc. (NASDAQ: NTRB) Is Outpacing Major Indicators

*Sponsored by Nutriband Inc. Breaking News Just Hit the Wire—As Krypton Street Announces Nutriband Inc. (NASDAQ: NTRB) Is Back On Our Radar  Thursday Morning, 2/13/2025. And Here’s Why… Low Float & Recent Market Recognition: With fewer than 5.1M shares in the float, (NTRB) has shown the potential for significant swings, including an approximate 202% move in one week. Technical Momentum: (NTRB) is trending above key moving averages, including the 50-day at $5.39, 100-day at $5.66, and the 200-day at $5.49, signaling continued momentum. High Insider Ownership & Analyst Target: Over 54% of shares are insider-held, and Noble Capital’s Robert LeBoyer recently set a $13 target, suggesting over 90% upside potential. Keep reading to see why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist today. February 13, 2025 Dear Reader, Ok let’s talk technicals for a minute. Nutriband Inc. (NASDAQ: NTRB) is currently trending above all major moving averages following its approx. 38% move this morning. Barchart reports the following moving averages for (NTRB): 5-Day: 7.38 20-Day: 7.23 50-Day: 5.46 100-Day: 5.69 200-Day: 5.51 Year-to-Date: 6.36 (NTRB) reached $9.88 in the early session, moving approximately 38% from yesterday’s $7.12 close.  For those who may have missed my earlier coverage on (NTRB), keep reading to quickly get up to speed.  From this morning’s breaking news—Nutriband Inc. (NASDAQ: NTRB) and Kindeva Dr-ug Delivery have taken a major step forward, locking in an exclusive product development partnership for Aversa™ Fent-a-nyl. This agreement solidifies Kindeva’s role in advancing Nutriband Inc. (NASDAQ: NTRB)’s abuse-deterrent transdermal technology while aligning both companies on shared development costs and milestone-based payments.   With a global patent portfolio and an NDA submission planned for late 2025, this move brings Nutriband Inc. (NASDAQ: NTRB) one step closer to commercializing what could be the first-ever abuse-deterrent fent-a-nyl patch. This under-the-radar pharma company has already turned heads twice, making approximate moves of 32% in under 24 hours and approx. 126% in less than 48 hours.  With this latest development, it’s back on our radar in a big way. Now, it’s going for the hat trick—and if you don’t know what that means, let’s clear it up. A hat trick is when the same player scores three times in a row.  And if this profile pulls it off again, anyone still sitting on the sidelines might start kicking themselves. Let’s not waste time. See why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning. Let’s call it like it is—few biotech companies are pushing boundaries quite like Nutriband Inc. (NASDAQ: NTRB). While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change. In fact, Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% in one week, from $3.90 on January 16th to $11.78 on January 23, 2025. Recently trending above several key moving averages, Nutriband Inc. (NASDAQ: NTRB) is showing strong technical momentum.  With its 50-day at $5.39, 100-day at $5.66, and 200-day at $5.49, (NTRB) is currently trending above all long-term indicators tracked by Barchart—a bullish signal that could suggest further upside potential.  Additionally, its year-to-date moving average of $6.29 reinforces the notion that (NTRB) has been maintaining strength despite broader market fluctuations. Backing this momentum, insider ownership stands at over 54% as of (yesterday) 2/12/2025—an exceptionally strong vote of confidence from those who know the company best.  With more than half of all shares held by insiders, leadership is signaling long-term commitment and belief in future growth. This combination of technical strength and a market cap under $77M, could position (NTRB) as a high-growth candidate compared to larger players in the same space. Less than a month ago, Noble Capital’s Robert LeBoyer initiated coverage on (NTRB) with a Bullish Rating and a $13 target, which suggests over 88% upside potential from yesterday’s $6.90 open.  At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, which is expected to showcase the effectiveness of its abuse-deterrent technology, setting up for an NDA filing by late 2025 and potential FDA approval in 2026. With a clear roadmap and strong momentum, Nutriband Inc. (NASDAQ: NTRB) continues to gain attention.  While many companies struggled to stay relevant, (NTRB) stayed on course, reinforcing its strategy and delivering results. Patent Strengthens Market Position Nutriband Inc. (NASDAQ: NTRB) received a Notice of Allowance from the USPTO for its Aversa™ abuse-deterrent transdermal technology. This expected patent issuance further strengthens its intellectual property portfolio and positions it as a key player in abuse-deterrent pharmaceuticals. Why It Matters Aversa™ Fent-a-nyl could be the first and only abuse-deterrent pain patch on the market, addressing a critical need in pain management.  With patents already granted in 46 countries, including the U.S., Europe, China, and Japan, (NTRB) is expanding its global footprint. If Aversa™ Fent-a-nyl reaches commercialization, U.S. sales projections range from $80M to $200M annually. Advancing AVERSA™ Fent-a-nyl Nutriband Inc. (NASDAQ: NTRB) is making strides toward bringing AVERSA™ Fent-a-nyl to market. Recent milestones include: Validation studies completed, moving the product closer to market readiness. Regulatory path established for an NDA submission in 2025 with a streamlined Phase 1 study. Potential to be the first abuse-deterrent opioid patch, addressing a major healthcare challenge. Global Intellectual Property & Expansion With patent approvals in 46 countries, including China and Hong Kong, (NTRB) is securing a dominant market position. A recent U.S. trademark allowance further cements its leadership in transdermal abuse-deterrent technology. Financial Growth & Strong Fiscal Position Nutriband Inc. (NASDAQ: NTRB) reported record-breaking revenues in 2024, driven by its subsidiary Pocono Pharma: Q3 revenue: a 51% YoY increase. Fiscal reserves strengthened with $8.4M in fresh capital from a private placement. This financial foundation supports the final push for AVERSA™ Fent-a-nyl’s commercialization. Regulatory Milestones and Market Readiness With an NDA submission planned for 2025, Nutriband Inc. (NASDAQ: NTRB) is working toward expedited FDA review. Meanwhile, manufacturing partnerships and global licensing agreements are positioning (NTRB) for scalability beyond the U.S. market. Beyond AVERSA™: Expanding the Pipeline Aversa™ Fent-a-nyl is just the beginning. Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications, with Buprenorphine alone estimated to reach $130M annually. Diversification & Innovation Nutriband Inc. (NASDAQ: NTRB) is expanding beyond pharmaceuticals with its consumer health and retail partnerships: Collaborations with Target, Walmart, Walgreens, and CVS. Exclusive supplier agreement with Fit For Life Group (Adidas, Reebok, New Balance). Launch of a Mosquito Repellent Patch in Costa Rica, tapping into the Central and South American markets. Why It Matters The opioid crisis remains one of the most pressing public health challenges. Nutriband Inc. (NASDAQ: NTRB) is not just talking about solutions—it’s delivering them.  AVERSA™ technology is designed to prevent misuse, accidental exposure, and abuse of high-risk transdermal drugs.  CEO Gareth Sheridan summed it up: Nutriband Inc. (NASDAQ: NTRB) is on the brink of a transformative period. Nutriband Inc. (NASDAQ: NTRB) Welcomes Olympian a to Advisory Board Nutriband Inc. (NASDAQ: NTRB) has announced that World and European Wrestling Gold Medalist and Olympic Silver Medalist Anastasia Nichita is joining its Product Advisory Board.  Her role will focus on expanding the Nutriband Brand and promoting its over-the-counter sports and consumer products on a global scale. CEO Gareth Sheridan highlighted Nichita’s addition as a strategic move to enhance the company’s market presence, citing her experience and influence in the athletic world.  Through its subsidiary Pocono Pharma, Nutriband produces various consumer products, including AI Tape, a kinesiology tape infused with soothing and therapeutic ingredients. With this high-profile appointment, Nutriband is reinforcing its commitment to innovation and brand expansion in the sports and wellness market. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is Topping Our Watchlist This Morning… 1. Low Float & Recent Market Recognition: With fewer than 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) has demonstrated the potential for significant swings, including an approximate 202% move in one week.  2. Technical Momentum: (NTRB) is trending above key moving averages, including the 50-day at $5.39, 100-day at $5.66, and 200-day at $5.49, with a year-to-date average of $6.29, signaling continued momentum. 3. High Insider Ownership & Analyst Target: Insider ownership stands at over 54% and Noble Capital’s Robert LeBoyer recently set a $13 target, suggesting over over 90% upside potential from yesterday’s range. 4. Patent Progress: A USPTO Notice of Allowance for its Aversa™ abuse-deterrent technology strengthens (NTRB)’s intellectual property and solidifies its role in abuse-deterrent pharmaceuticals. 5. Regulatory & Market Expansion: With an NDA submission expected in late 2025, Aversa™ Fent-a-nyl could become the first and only abuse-deterrent fent-a-nyl patch, with projected U.S. sales of $80M to $200M annually. 6. Strong Fiscal Backing: (NTRB) reported a 51% year-over-year revenue increase and secured $8.4M in fresh capital, reinforcing its potential for growth and product development. 7. Global Reach & Diversification: With patents in 46 countries, including the U.S., Europe, China, and Japan, (NTRB) is expanding internationally while also partnering with Target, Walmart, Walgreens, and CVS in consumer health. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to Your  Radar This Morning… Let’s be honest—Nutriband Inc. (NASDAQ: NTRB) isn’t your run-of-the-mill biotech.  With a low float, strong technical momentum, and a patent portfolio spanning 46 countries, this company is making moves that demand attention.  Add in a game-changing abuse-deterrent technology, insider confidence at over 54%, and an analyst target suggesting over 90% upside potential, and you’ve got a profile that doesn’t sit quietly. And let’s not forget, Aversa™ Fent-a-nyl isn’t just another patch—it has the potential to be the first and only abuse-deterrent fent-a-nyl patch in the market, with projected U.S. sales between $80M and $200M annually.  That’s not just a milestone—it’s a potential market shift. With a recently granted patent allowance and today’s news adding to the momentum, we’ll be keeping a close watch on what happens next. We have all eyes on (NTRB) this morning.  Nutriband Inc. (NASDAQ: NTRB) is currently trending above all major moving averages following its approx. 38% move this morning. Are you watching (NTRB) yet? Keep an eye out for my next update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 02/13/2025 and ending on 02/14/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Media 1717 LLC has been paid an seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid twenty-two thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/ntrb/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice